Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97582 | 0.86 | CA1 (0.52) | GFERESR1ESR2CA2CA1 | |
| SCHEMBL2990802 | 0.85 | MAOB (0.56) | MAOAMAOBTAAR1HDAC1FFAR1 | |
| SCHEMBL16663974 | 0.85 | TAAR1 (0.56) | MAOBTAAR1 | |
| SCHEMBL30965275 | 0.84 | MAOB (0.44) | ESR1CA2CA1MAOAMAOB | |
| SCHEMBL9192375 | 0.84 | CA2 (0.42) | GFERESR1ESR2CA2CA1 | |
| SCHEMBL12401893 | 0.84 | HTR2A (0.44) | GFERESR1ESR2CA2CA1 | |
| SCHEMBL2990337 | 0.83 | TAAR1 (0.54) | MAOAMAOBTAAR1 | |
| SCHEMBL28372503 | 0.81 | ALDH1A1 (0.52) | GFERESR1ESR2CA2CA1 | |
| SCHEMBL28277706 | 0.79 | CA1 (0.39) | GFERESR1ESR2CA2CA1 | |
| SCHEMBL8148458 | 0.79 | CA2 (0.59) | ESR1ESR2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | GLOBAVIR BIOSCIENCES, INC. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | EGLN3, HIF1AN, EGLN2 | GFER 4364/4885ESR1 571/4885ESR2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.